Bristol-Myers Squibb SVP: IP Strategy Essential to Drug Development Process

As senior vice president and deputy general counsel for Bristol-Myers Squibb since 2011, Henry Hadad has helped the company navigate the complex intellectual property issues inherent in the successful development and commercialization of new drugs. He shares his thoughts on some of the most effective practices to manage the process.

What are the main challenges facing the pharmaceutical industry for effectively valuing a company’s intellectual property where ongoing research and development is also a factor?

Intellectual property protection is a key consideration when dealing with a life sciences acquisition or license. Given the uncertainty and cost of drug discovery and ...